Verona Pharma plc Stock

Equities

VRNA

US9250501064

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-08 pm EDT 5-day change 1st Jan Change
14.88 USD +0.61% Intraday chart for Verona Pharma plc -2.23% -25.15%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 11.88M 14.84M Sales 2025 * 88.56M 111M Capitalization 965M 1.21B
Net income 2024 * -87M -109M Net income 2025 * -49M -61.23M EV / Sales 2024 * 65.7 x
Net cash position 2024 * 184M 230M Net cash position 2025 * 146M 183M EV / Sales 2025 * 9.24 x
P/E ratio 2024 *
-23.9 x
P/E ratio 2025 *
-44.4 x
Employees 79
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75.42%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower MT
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 CI
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT
Piper Sandler Raises Verona Pharma's Price Target to $36 From $31, Keeps Overweight Rating MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading MT
Verona Pharma plc Announces Management Changes CI
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat MT
Verona Pharma Shares Rise After Narrower-Than-Expected Q4 Loss MT
More news
1 day+0.61%
1 week-2.23%
Current month-3.69%
1 month-11.85%
3 months-8.60%
6 months+5.46%
Current year-25.15%
More quotes
1 week
14.60
Extreme 14.6
15.87
1 month
14.60
Extreme 14.6
16.57
Current year
14.60
Extreme 14.6
20.67
1 year
11.83
Extreme 11.83
23.81
3 years
3.41
Extreme 3.4078
26.44
5 years
0.00
Extreme 0
26.44
10 years
0.00
Extreme 0
26.44
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 20-01-31
Director of Finance/CFO 61 20-02-29
Chief Tech/Sci/R&D Officer - 22-12-31
Members of the board TitleAgeSince
Director/Board Member 79 16-06-16
Director/Board Member 60 16-09-11
Chairman 69 14-11-30
More insiders
Date Price Change Volume
24-05-08 14.88 +0.61% 422,783
24-05-07 14.79 -1.07% 328,543
24-05-06 14.95 -4.72% 601,004
24-05-03 15.69 -0.38% 507,486
24-05-02 15.75 +3.48% 689,321

Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT

More quotes
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual inhibition enables it to act as a bronchodilator and a non-steroidal anti-inflammatory agent . It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
14.88 USD
Average target price
33.67 USD
Spread / Average Target
+126.25%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW